Substituted Isoquinolinones Inhibit MDM2-p53 Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for proliferative diseases, such as tumors and leukemias, are hindered by the dysregulation of the MDM2/p53 ratio, leading to uncontrolled cell proliferation due to MDM2's inhibition of p53's tumor suppressor activity, necessitating new drugs that can interfere with the MDM2/p53 interaction to restore p53's regulatory functions.
Innovation Solution
Development of a novel class of substituted nitrogen-containing bicyclic heterocycles that inhibit the interaction between p53 and MDM2 or MDM4, allowing p53 to exert its tumor suppressor effects by binding to these proteins and potentially arresting cell cycle progression or inducing apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If MDM2 or MDM4 is overexpressed, then cell proliferation is promoted, but tumor suppressor activity is inhibited
Solution Approach 1:
The patent introduces small molecule compounds as intermediary substances that bind to MDM2 or MDM4 proteins, preventing their interaction with p53. These compounds act as mediators that block the harmful interaction between MDM2/MDM4 and p53, thereby restoring tumor suppressor activity without directly causing cell death or proliferation.
Solution Approach 2:
The patent modifies the chemical structure and binding characteristics of the compounds to optimize their interaction with MDM2/MDM4. By changing parameters such as binding affinity, selectivity, and cellular uptake, the compounds effectively alter the MDM2/p53 ratio dynamics, restoring p53's tumor suppressor function while managing cell proliferation.
2Reliability
If p53 is inhibited by MDM2, then uncontrolled cell growth occurs, but restoring p53 activity requires new therapeutic compounds
Solution Approach 1:
The patent divides the complex problem of restoring p53 activity into specific target areas by designing compounds that selectively bind to specific regions of MDM2 or MDM4 proteins. This segmentation allows for targeted interference with the MDM2/p53 interaction mechanism, making drug development more systematic and manageable.
Solution Approach 2:
The patent creates synthetic compounds that mimic or interfere with the natural binding interface between MDM2 and p53. By designing molecules that copy the structural features of the MDM2-p53 interaction interface, the compounds can effectively block this interaction, providing a strategy for restoring p53 function.
3Reliability
If MDM2/p53 interaction is restored, then cell cycle arrest or apoptosis occurs, but current treatments are limited
Solution Approach 1:
The patent develops compounds that can potentially target multiple mechanisms within the MDM2/p53 pathway, providing multi-functional activity. These compounds may simultaneously inhibit MDM2 binding to p53, prevent MDM4 interaction, and restore various aspects of p53 function including cell cycle arrest and apoptosis induction, thereby expanding treatment options.
Data Source
AI summary
The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I)wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.